AGC Biologics S.p.A.
20
0
0
18
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
10.0%
2 terminated/withdrawn out of 20 trials
90.0%
+3.5% vs industry average
10%
2 trials in Phase 3/4
28%
5 of 18 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor
Role: collaborator
A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors
Role: lead
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
Role: lead
Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Role: lead
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma
Role: lead
Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
Role: lead
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Role: lead
Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
Role: lead
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
Role: lead
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM
Role: lead
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
Role: lead
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
Role: lead
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer
Role: lead
NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer
Role: lead
Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
Role: lead
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
Role: lead
Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies
Role: lead
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
Role: lead
Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor
Role: lead
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Role: lead
All 20 trials loaded